logo
These are the top workplace fears for U.S. employees right now

These are the top workplace fears for U.S. employees right now

Yahoo18-04-2025
At the start of the year, a survey from workplace platform Modern Health identified that a huge 75 percent of the American workforce said they were experiencing some form of low mood.
Unsurprisingly, politics and current events are the key drivers of U.S. workers' worries.
Workers' mental health is taking a beating as a result, with 74 percent saying they want mental-health resources specifically addressing global political turmoil.
For many employees, things are as bad as they've ever been. Almost half of the survey respondents said life was easier during the COVID-19 pandemic than it is now.
Executive Director, ROA, Washington D.C.
Director of Policy – North America, Ellen MacArthur Foundation, Washington D.C. or New York City
Senior Campaigner (17-Month Fixed Term), Amnesty International USA, New York City / Washington D.C.
Director of Government Affairs, Blueprint Biosecurity, Washington D.C.
'American employees are struggling with their mental health, with global political turmoil and current events taking a particularly dire toll, and it's detrimental to how employees are showing up in the workplace,' says Alyson Watson, founder, and CEO of Modern Health.
Those factors are bad enough, but another piece of research identifies that a majority of Americans are also concerned about the prospect of losing their job this year.
Another study, conducted by My Perfect Resume, outlines growing fears among workers.
Eighty-one percent are afraid they'll lose their job in 2025, and 20 percent of those are 'much more worried' about finding themselves unemployed in 2025 than they were a year ago.
Adding to that are fears that finding a new job won't be easy, with 57 percent expecting that finding a new position will be as difficult or harder than it was in 2024.
Even more worries are weighing hard on workers' minds. Ninety-two percent are concerned about a recession this year, and 33 percent believe the overall labor market will worsen.
Burnout is on the rise with workers' saying that increased workloads (29 percent), and lack of work-life balance (23 percent), are the significant contributing factors.
For those who have already been hit by job cuts this year, former president Joe Biden's recent comments at the national conference of Advocates, Counselors and Representatives for the Disabled (ACRD) in Chicago, may have hit home.
Biden hit out at cuts at the Social Security Administration and said a 'hatchet' had been taken to the organization.
'Already we can see the effects, for example, thousands of people who use the Social Security website every single day to check on their benefits and submit their claims,' he said.
'But now, the technology division of the Social Security administration has been cut in half. And so the website's crashing. People can't sign onto their accounts. What do you think it does?'
American workers are also concerned about the erosion of remote and hybrid working.
Eighty-eight percent of respondents to My Perfect Resume's study said they predict more companies will require employees to return to the office this year.
While the most recent report from WFH Research, which monitors working from home before and since the start of the pandemic, found that these days, working from home is most common in the finance, tech, and professional and business services sectors.
It also identified that 13 percent of full-time employees are now fully remote, 61 percent are full-time on site, and 26 percent are working in a hybrid manner.
It is clear that as a result of waves of return to office mandates, fewer workers than before are able to enjoy a completely remote setup.
However, some light has emerged at the end of the tunnel for workers at the Food and Drug Administration, for example.
Just weeks after workers there were ordered back into the office, and were met with a range of issues like limited parking and makeshift office spaces, the agency has had a change of heart. It will now allow certain staff to work remotely, such as its review staff and supervisors.
In general however, jobs are trending away from offering remote working. LinkedIn statistics show that just 8 percent of jobs were remote as of December 2024. That's down from 18 percent in early 2022.
One outlier has emerged here, however: high paying, in-demand positions are still more likely to be offered for remote working.
Career site Ladders found that 10.4 percent of roles that pay $250,000 or more were advertised as remote in the third quarter of 2024.
The takeaway is that if you've got skills that are in demand in the labor market, you've still got negotiating power to work the way that suits you.
Get your job search underway: Browse thousands of jobs on The Hill Job Board
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump administration imposes fresh sanctions on ICC officials
Trump administration imposes fresh sanctions on ICC officials

Axios

time2 minutes ago

  • Axios

Trump administration imposes fresh sanctions on ICC officials

The Trump administration announced fresh sanctions on International Criminal Court officials on Wednesday and accused the ICC of being a "national security threat" and "instrument for lawfare" against the U.S. and Israel. The big picture: The intergovernmental organization and international tribunal in a statement called the latest U.S. sanctions that affect two judges and two prosecutors "a flagrant attack against the independence of an impartial judicial institution." Driving the news: Rubio said in a statement posted to the State Department's website that the sanctions were in response to the "ICC's Ongoing Threat to Americans and Israelis." The sanctioned officials "directly engaged" in ICC efforts "to investigate, arrest, detain, or prosecute nationals of the United States or Israel, without the consent of either nation." The latest penalties that effective freeze assets and bar officials from entering the U.S. affect ICC judges Kimberly Prost, of Canada, and Nicolas Guillou, of France, and prosecutors Nazhat Shameem Khan, of Fiji, and Mame Mandiaye Niang, of Senegal, according to the statement. State of play: President Trump first imposed sanctions on ICC officials in a February executive order, some three months after the court that neither the U.S. nor Israel recognizes issued arrest warrants for Netanyahu and former Minister of Defense Yoav Gallant for alleged war crimes and crimes against humanity during the war in Gaza. In June, Rubio announced sanctions on four ICC judges over the arrest warrants and also due to the court's investigation into alleged U.S. war crimes in Afghanistan. Zoom in: "Prost is being designated for ruling to authorize the ICC's investigation into U.S. personnel in Afghanistan," per a State Department statement. Guillou was targeted for ruling to authorize the ICC arrest warrants for Netanyahu and Gallant, while the statement said Shameem Khan and Niang were being designated "for continuing to support illegitimate ICC actions against Israel." This included the upholding of the arrest warrants.

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Indianapolis Star

time3 minutes ago

  • Indianapolis Star

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

SHELTON, CONNECTICUT / ACCESS Newswire NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by awakening of 'sleeping' cancer cells due to viral infections. NV-387 has successfully completed a Phase I clinical trial and is being advanced into Phase II clinical trials. Recently, increase in inflammation, and particularly the cytokine IL-6, caused by viral infections has been found to be linked to an increased risk of resurgence of metastatic cancer, in a study of COVID-19 (SARS-CoV-2 infection) and breast cancer, as well as Influenza virus infections and cancer [1] . This study has further substantiated that viral infections can lead to resurgence of metastatic cancers by re-activating 'sleeping' cancer cells. 'NV-387 is a remarkable antiviral drug, in that it not only attacks the virus, but also reduces inflammation, calming the human immune system so that untoward effects do not take place,' said Anil R. Diwan, Ph.D., President and Chairman of the Company, adding, 'We have found that NV-387 treatment reduces inflammation markers, particularly, IL-6, thereby protecting lungs. This reduction in inflammation and cyto-protective effect of NV-387 would also help minimize the risk of reawakening cancer, based on these reported studies.' Thus NV-387 treatment could have a strong impact in the treatment of cancer patients in remission who suffer from a viral infection that could lead to the cancer returning with metastasis to multiple sites in the body. COVID-19 has become endemic globally, with generally two waves every year. The summer surge is already occurring in the USA, with approximately 4,000 hospitalizations per week in the week ending July 26 at the beginning of the surge, fueled by ever-changing variants [2] . Influenza virus is a well-known endemic virus that causes pandemics globally. RSV is an endemic virus that causes particularly severe diseases in infants and children as well as adults. Measles virus causes 'immune system amnesia' and is increasing globally. NV-387 is the only antiviral drug that has been uniquely found to be effective in the treatment of lethal lung viral infections caused by all of these viruses in animal model studies that are predictive of human clinical effectiveness. This clearly demonstrates the unmet medical need for NV-387, a broad-spectrum antiviral that the viruses cannot escape even as new variants are created. In contrast, antibodies and vaccines readily fail with new variants arising, as is now well known. NV-387 treatment has been found to reduce the level of IL-6 in lethal viral infections causing lung diseases in animal models. Excellent protection of lungs was found to occur in NV-387-treated animals but not in ribavirin treated animals in a lethal RSV infection study. Strong protection of lungs was found to occur in NV-387-treated animals in a lethal lung-infection of Influenza A/H3N2 study. In this Influenza study, the approved drugs Tamiflu (oseltamivir), Rapivab (peramivib), and Xofluza (baloxavir) failed to protect the lungs of animals to any appreciable extent, indicating the superiority and clinical viability of NV-387. The Company further investigated the extra-ordinary effect of NV-387 on protection of lungs in lethal viral infections. Reduction in inflammatory cytokines, particularly IL-6, was found to occur to an appreciable extent in NV-387 treated animals. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Public Relations Contact: ir@ [1] Publication: 'Respiratory viral infections awaken metastatic breast cancer cells in lungs', Chia et al, J DeGregori group, [2] Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2025, August 18. SOURCE: NanoViricides, Inc. View the original press release on ACCESS Newswire The post A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials appeared first on DA80 Hub.

Trump Turns Up the Heat. Fed Chair Jerome Powell Tries to Keep His Cool.
Trump Turns Up the Heat. Fed Chair Jerome Powell Tries to Keep His Cool.

Wall Street Journal

time33 minutes ago

  • Wall Street Journal

Trump Turns Up the Heat. Fed Chair Jerome Powell Tries to Keep His Cool.

Minutes before his congressional testimony this summer, Jerome Powell sat alone, staring straight ahead in the wood-paneled chamber, appearing deep in thought. The Federal Reserve chair later told an associate he felt locked in, prepared for questions about the central bank's chief roles—keeping inflation low and Americans employed. Powell looked steeled for criticism, and he didn't have to wait long.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store